Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology‐pathology correlation and survival of radiation segmentectomy

Michael Vouche, Ali Habib, Thomas J. Ward, Edward Kim, Laura Kulik, Daniel Ganger, Mary Mulcahy, Talia Baker, Michael Abecassis, Kent T. Sato, Juan‐Carlos Caicedo, Jonathan Fryer, Ryan Hickey, Elias Hohlastos, Robert J. Lewandowski, Riad Salem – 6 February 2014 – Resection and radiofrequency ablation (RFA) are treatment options for hepatocellular carcinoma (HCC) <3 cm; there is interest in expanding the role of ablation to 3‐5 cm. RFA is considered high‐risk when the lesion is in close proximity to critical structures.

Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology‐pathology correlation and survival of radiation segmentectomy

Michael Vouche, Ali Habib, Thomas J. Ward, Edward Kim, Laura Kulik, Daniel Ganger, Mary Mulcahy, Talia Baker, Michael Abecassis, Kent T. Sato, Juan‐Carlos Caicedo, Jonathan Fryer, Ryan Hickey, Elias Hohlastos, Robert J. Lewandowski, Riad Salem – 6 February 2014 – Resection and radiofrequency ablation (RFA) are treatment options for hepatocellular carcinoma (HCC) <3 cm; there is interest in expanding the role of ablation to 3‐5 cm. RFA is considered high‐risk when the lesion is in close proximity to critical structures.

Relationship of hepatitis C virus infection with diabetes in the U.S. population

Constance E. Ruhl, Andy Menke, Catherine C. Cowie, James E. Everhart – 5 February 2014 – An association of hepatitis C virus (HCV) infection with diabetes has been reported in many studies, but few have been population based and applied standard criteria for diabetes diagnosis. We examined this relationship using recent population‐based data from the U.S. National Health and Nutrition Examination Survey. Adult participants (15,128) in the 1999‐2010 surveys had data on diabetes status and serum HCV antibody (anti‐HCV) or HCV RNA.

All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐naïve patients with genotype 1 HCV infection

David L. Wyles, Maribel Rodriguez‐Torres, Eric Lawitz, Mitchell L. Shiffman, Stanislas Pol, Robert W. Herring, Benedetta Massetto, Bittoo Kanwar, James D. Trenkle, Phil S. Pang, Yanni Zhu, Hongmei Mo, Diana M. Brainard, G. Mani Subramanian, John G. McHutchison, François Habersetzer, Mark S.

Subscribe to